Frias JP, Nauck MA, Van J, Kutner ME, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018 Oct 3. pii: S0140-6736(18)32260.
PMID: 30293770